A common founder for the V126D CDKN2A mutation in seven north american melanoma-prone families

British Journal of Cancer

Volumn 85, Issue 4, 2001, Pages 527-530

  Goldstein, A M ^a   Liu, L ^b   Shennan, M G ^c   Hogg, D ^b,c   Tucker, M A ^a   Struewing, J P ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

CDKN2A; Founder; Melanoma; V126D

Indexed keywords

CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 2A; GENE PRODUCT; PROTEIN P14; PROTEIN P16; UNCLASSIFIED DRUG;

ARTICLE; CANCER SUSCEPTIBILITY; FAMILIAL CANCER; FOUNDER EFFECT; GENE MUTATION; GENETIC MARKER; GERM LINE; HAPLOTYPE; HUMAN; MELANOMA; NORTH AMERICA; PRIORITY JOURNAL;

CANADA; DNA MUTATIONAL ANALYSIS; FOUNDER EFFECT; GENES, P16; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MELANOMA; PEDIGREE; SKIN NEOPLASMS; UNITED STATES;

EID: 0035902848     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2001.1944     Document Type: Article

References (25)

1. Novel germline p16 mutation in familial melanoma in southern Sweden
2. Malignant melanoma: Modern black plague and genetic black box
3. A single genetic origin for the G101W CDKN2A mutation in 20 melanoma-prone families
4. Characterization of ligurian melanoma families and risk of occurrence of other neoplasia
5. Genotype-phenotype relationships in American melanoma-prone families with CDKN2A and CDK4 mutations
6. Familial melanoma and its management
7. Homozygotes for CDKN2A (p16) germline mutation in Dutch familial melanoma kindreds
8. Haplotype analysis and age estimation of the 113 insArg CDKN2A founder mutation in Swedish melanoma families
9. Germline p16 mutations in familial melanoma
10. Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: A consensus statement of the Melanoma Genetic Consortium
11. Mutation of the CDKN2A 5′ UTR creates an aberrant initiation codon and predisposes to melanoma
12. CDKN2A germline mutations in U.K. patients with familial melanoma and multiple primary melanomas
13. Haplotype and phenotype analysis of six recurrent BRCA1 mutations in 61 families: Results of an international study
14. Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: Results of an international study
15. Mutation testing in melanoma families: INK4A CDK4, and INK4DM
16. Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma
17. Haplotype Analysis of two recurrent CDKN2A mutations in 10 melanoma families: Evidence for common founders and independent mutations
18. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53
19. Mutations associated with familial melanoma impair p161NK4 function
20. ARF but not CDKN2A in a melanomaneural system tumour syndrome family
21. CDKN2A mutations in Spanish cutaneous malignant melanoma families and patients with multiple melanoma and other neoplasia
22. A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/CDK4
23. Inhibition of ras-induced proliferation and cellular transformation by p 161NK4
24. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France
25. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways